Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on June 28, 2023. The report details a specific corporate event regarding an amendment to a licensing agreement rather than a standard periodic financial report.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is an optional additional license fee of $2,500 associated with the agreement amendment.
Material Changes
On June 28, 2023, the Company entered into an amendment to its Commercial Evaluation and License Agreement (CELA) with the University of Maryland, Baltimore (UMB), originally dated February 26, 2021. The material changes include:
- Extension of the CELA term until September 30, 2023.
- Option for the Company to further extend the CELA until December 31, 2023.
- Conditions for the optional extension: written notice to UMB by August 31, 2023, and payment of the $2,500 fee.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the amendment. The filing notes that the summary is qualified by reference to the full Amendment text filed as Exhibit 99.1. No specific risks, contingencies, or forward-looking guidance regarding financial performance are provided in this document.
Key Facts for Investor Verification
- Verify the status of the optional extension to December 31, 2023, and whether the $2,500 fee was paid by the August 31, 2023 deadline.
- Review the full text of the Fifth Amendment (Exhibit 99.1) for any additional terms or obligations not summarized in the 8-K.
- Confirm the current operational status of the commercial evaluation with the University of Maryland, Baltimore.